(Total Views: 403)
Posted On: 07/01/2025 10:06:30 PM
Post# of 154880
Re: chazzledazzle #154780
On Linkedin Dr Max L commented to Ken Chowder.
" Very good question Ken ! As you pointed out ,CRC is known to be a cold tumor not much PD-L1 expression . We hope to see a similar impact on PD-L1 upregulation prospectively with leronlimab , allowing patients potentially to benefit from ICIs .
That option has been added in CRC study .
Best. "
So from the above I feel it is a good chance these patients with elevated PD-L1 will receive ICIs , but we don't know this from the company so I am not sure.
" Very good question Ken ! As you pointed out ,CRC is known to be a cold tumor not much PD-L1 expression . We hope to see a similar impact on PD-L1 upregulation prospectively with leronlimab , allowing patients potentially to benefit from ICIs .
That option has been added in CRC study .
Best. "
So from the above I feel it is a good chance these patients with elevated PD-L1 will receive ICIs , but we don't know this from the company so I am not sure.
(11)
(0)
